Alopecia areata: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• JAK 1
• CTLA-4 0
• G6PD 0
• GLP-1 0
• IL-17 0
• NLRP3 0
• TNF 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 335 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

  NCT06444451· Sanofi· Updated 10 Aug 2026

  “Sponsor decision; the decision is not related to any safety concern”Registry text, quoted unchanged. Source

• Terminated

  A Study of KL130008 in Adults With Severe Alopecia Areata

  NCT05496426· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Updated 12 May 2026

  “This adjustment to the company's development strategy is unrelated to safety or efficacy.”Registry text, quoted unchanged. Source

• Terminated

  DPCP for the Treatment of Alopecia Areata

  NCT03651752· University of Minnesota· Updated 26 Jan 2026

  “The study was paused/enrollment on hold after 4 screen failed subjects. No further subjects were enrolled, therefore, no data was available to collect/analyze.”Registry text, quoted unchanged. Source

• Terminated

  PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

  NCT04517864· Pfizer· Updated 11 Jul 2025

  “For business reasons”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

  NCT05556265· Bristol-Myers Squibb· Updated 31 May 2025

  “Business objectives have changed”Registry text, quoted unchanged. Source

• Terminated

  Mechanical Intervention on the Scalp Microbiome: Setting the Stage for the Future Management of Cicatricial Alopecias

  NCT06357169· University of Minnesota· Updated 12 Feb 2025

  “There was only one participant”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

  NCT07029711· Pfizer· Source

• A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

  NCT07533006· Eli Lilly and Company· Source

• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

  NCT05723198· Eli Lilly and Company· Source

• A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata

  NCT07772492· AbbVie· Source

• A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

  NCT07733765· Pfizer· Source

• A study in young people and adults to learn about the medicine ritlecitinib for treatment of patchy hair loss, known by the medical term as moderate alopecia areata

  2026-526355-62-00· Pfizer Inc.· Source

• A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

  NCT06873945· Pfizer· Source

• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

  NCT06012240· AbbVie· Source

• A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

  NCT07029828· Pfizer· Source

• Dupilumab in the Treatment of Pediatric Alopecia Areata

  NCT05866562· Icahn School of Medicine at Mount Sinai· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Mendelian Randomization Analysis 5
• Gene Expression Profiling 6
• Sequence Analysis, RNA 1
• Proteomics 1
• Flow Cytometry 1
• Immunohistochemistry 2
• Magnetic Resonance Imaging 1
• Machine Learning 3
• Cohort Studies 3
• Genome-Wide Association Study 5

• Risk of inflammatory dermatoses following COVID-19 infection: a cohort study of 204 241 patients.

  Clin Exp Dermatol, May 2026

• Real-World Safety of JAK Inhibitors in Skin Immune-Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study.

  Clin Pharmacol Ther, Mar 2026

• Global landscape of autoimmune diseases across different lifespan: A three-decade perspective.

  Medicine (Baltimore), Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.